31 March 2021 in Journal of Magnetic Resonance Imaging
Background: Diffusion magnetic resonance imaging (MRI) is integral to detection of prostate cancer (PCa), but conventional apparent diffusion coefficient (ADC) cannot capture the complexity of prostate tissues and tends to yield noisy images that do not distinctly highlight cancer. A four‐compartment restriction spectrum imaging (RSI4) model was recently found to optimally characterize pelvic diffusion signals, and the model coefficient for the slowest diffusion compartment, RSI4‐C1, yielded greatest tumor conspicuity.Purpose: To evaluate the slowest diffusion compartment of a four‐compartment spectrum imaging model (RSI4‐C1) as a quantitative voxel‐level classifier of PCa.Study Type: Retrospective.Subjects: Forty‐six men who underwent an extended MRI acquisition protocol for suspected PCa. Twenty‐three men had benign prostates, and the other 23 men had PCa.Field Strength/Sequence: A 3 T, multishell diffusion‐weighted and axial T2‐weighted sequences.Assessment: High‐confidence cancer voxels were delineated by expert consensus, using imaging data and biopsy results. The entire prostate was considered benign in patients with no detectable cancer. Diffusion images were used to calculate RSI4‐C1 and conventional ADC. Classifier images were also generated.Statistical Tests: Voxel‐level discrimination of PCa from benign prostate tissue was assessed via receiver operating characteristic (ROC) curves generated by bootstrapping with patient‐level case resampling. RSI4‐C1 was compared to conventional ADC for two metrics: area under the ROC curve (AUC) and false‐positive rate for a sensitivity of 90% (FPR90). Statistical significance was assessed using bootstrap difference with two‐sided α = 0.05.Results: RSI4‐C1 outperformed conventional ADC, with greater AUC (mean 0.977 [95% CI: 0.951–0.991] vs. 0.922 [0.878–0.948]) and lower FPR90 (0.032 [0.009–0.082] vs. 0.201 [0.132–0.290]). These improvements were statistically significant (P < 0.05).Data Conclusion: RSI4‐C1 yielded a quantitative, voxel‐level classifier of PCa that was superior to conventional ADC. RSI classifier images with a low false‐positive rate might improve PCa detection and facilitate clinical applications like targeted biopsy and treatment planning.Evidence Level: 3Technical Efficacy: Stage 2
22 March 2016 in Chemical Science
CAChristopher M. Andolina
+4
A Gd3+-coordinated polymerizable analogue of the MRI contrast agent Gd-DOTA was used to prepare amphiphilic block copolymers, with hydrophilic blocks composed entirely of the polymerized contrast agent.
14 December 2021 in Magnetic Resonance in Medicine
20 May 2017 in Journal of Clinical Oncology
2512 Background: Precision medicine has been studied in patients (pts) with advanced, heavily-treated cancers by administering molecularly matched monotherapies. With increasing availability of large gene assays and cognate agents, we hypothesized that offering customized combination therapies to treatment-naïve tumors would be feasible and improve response rates. Methods: Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT, NCT02534675) targeted metastatic and/or unresectable, untreated lethal cancers ( > 50% 2-yr mortality). Comprehensive genomic profiling (CGP, Foundation Medicine; 315 genes), and, if possible, PD-(L)1 IHC, tumor mutational burden (TMB) and circulating tumor DNA were performed. A molecular tumor board discussed results immediately upon receipt, and emphasized customized combinations. Final decisions were the treating physician’s choice. Results: CGP was evaluable in 40/47 treatment-naïve pts (85.1%); 22 (46.8%) were treated [17 matched (36.2%); 5 unmatched (10.6%); 11 different diagnoses). The other 25 pts (53.2%) are awaiting therapy (8, 17%) or could not be treated (17, 36.2%), mainly due to patient deterioration or payor limitations. Each tumor had a unique genomic portfolio. The median (range) of genomic alterations/patient was 5 (1-12). TMB was available in 17 pts (12 low; 4 intermediate; 1 high). The median (range) Matching Score [(matches (#)/characterized genomic alterations (#)] was 33% (14-100%; 100% designated immunotherapy match or all alterations matched to targeted agents) [Reference PMID 2719717]. Nine/17 matched pts (53%) achieved SD > 6 months (N = 2) or CR (1)/PR (6). The median progression-free survival (PFS) for matched vs. unmatched pts was 4.7 vs. 1.0 months ( P= 0.0019). There were no drug-related deaths. Conclusions: With the use of broad-based DNA sequencing assays, inclusion of pts earlier in their disease course, timely mandated molecular tumor board discussions, and increasing availability of cognate drugs for customized combinations, we report: 1) high molecular matching rates (~36%); 2) high rates of SD > 6 months/CR/PR (~53%); and 3) improved PFS. Study expansion is ongoing. Clinical trial information: NCT0253467.
1 January 2023 in Radiology: Imaging Cancer
Purpose To develop a multicompartmental signal model for whole-body diffusion-weighted imaging (DWI) and apply it to study the diffusion properties of normal tissue and metastatic prostate cancer bone lesions in vivo. Materials and Methods This prospective study (ClinicalTrials.gov: NCT03440554) included 139 men with prostate cancer (mean age, 70 years ± 9 [SD]). Multicompartmental models with two to four tissue compartments were fit to DWI data from whole-body scans to determine optimal compartmental diffusion coefficients. Bayesian information criterion (BIC) and model-fitting residuals were calculated to quantify model complexity and goodness of fit. Diffusion coefficients for the optimal model (having lowest BIC) were used to compute compartmental signal-contribution maps. The signal intensity ratio (SIR) of bone lesions to normal-appearing bone was measured on these signal-contribution maps and on conventional DWI scans and compared using paired t tests (α = .05). Two-sample t tests (α = .05) were used to compare compartmental signal fractions between lesions and normal-appearing bone. Results Lowest BIC was observed from the four-compartment model, with optimal compartmental diffusion coefficients of 0, 1.1 × 10-3, 2.8 × 10-3, and >3.0 ×10-2 mm2/sec. Fitting residuals from this model were significantly lower than from conventional apparent diffusion coefficient mapping (P < .001). Bone lesion SIR was significantly higher on signal-contribution maps of model compartments 1 and 2 than on conventional DWI scans (P < .008). The fraction of signal from compartments 2, 3, and 4 was also significantly different between metastatic bone lesions and normal-appearing bone tissue (P ≤ .02). Conclusion The four-compartment model best described whole-body diffusion properties. Compartmental signal contributions from this model can be used to examine prostate cancer bone involvement. Keywords: Whole-Body MRI, Diffusion-weighted Imaging, Restriction Spectrum Imaging, Diffusion Signal Model, Bone Metastases, Prostate Cancer Clinical trial registration no. NCT03440554 Supplemental material is available for this article. © RSNA, 2023 See also commentary by Margolis in this issue.